Due to the listing of brain-computer connection, all the main contents of the prospectus of Science and Technology Biotechnology must be redone.

The most important content in the prospectus is the valuation of the company, the company's total share capital and issue price.

Originally, three underwriters, CICC, CITIC Construction Investment and CITIC Securities, held no less than ten joint meetings with the six major shareholders of Sci-Tech Biotechnology, before finalizing these.

Li Miaomiao attended the meeting as Zheng Li's plenipotentiary representative.

Now we have to push it back.

Since Science and Technology Biotech only issues quarterly reports to major shareholders, shareholders such as IDC and Temasek account for a small proportion of shares, they cannot participate in the daily operations of the company and at most participate in the decision-making of the board of directors.

But since Li Zheng is not in Gusu, the board of directors has never been held very well.

The 2020 annual report still states that the application research and development of brain-computer connection devices on mobile phones is expected to be completed in 2021.

The first quarter report has not been received yet, but I didn’t know that Zheng Li’s progress is so fast. He completed the signing of patent authorization contracts with major manufacturers in January.

The contract with Dami was also signed in the first quarter, but due to a private agreement with Lei Jun, the laboratory testing equipment was provided to Dami in advance.

Of course, IDC Capital, Temasek, and Goldman Sachs received news earlier than the news. They received news after the patent authorization of Science and Technology Bio-Brain Computer Connection was approved.

It was too late to get the news, but the listing materials had not been submitted to the stock exchange, and major shareholders asked to revalue the valuation of Science and Technology Biotechnology.

It is impossible to value the value according to the value of a single endorphin after there is a brain-computer connection.

Li Shuyao said: "There is a very critical question. Can I ask in advance?"

Li Miaomiao knew that it would be a problem that would make her difficult, otherwise Li Shuyao would ask directly, "Tell me."

"Will iPhone13 have a brain-computer connection function? If iPhone13 has a brain-computer connection function, I really want to change it."

Li Miaomiao: "Tell the truth."

Li Shuyao lowered her head and said, "I just want to know whether Science and Technology Biotech has signed a contract with Apple, or whether you have any intention to reach a cooperation plan now. If the profit in 2021 is reached, it is expected to have a completely different valuation."

Li Miaomiao realized that in some aspects, she had a deeper understanding than her sister who graduated from finance and studied for a postgraduate degree at Yenching University.

She has a deeper understanding of the teacher who is the best experience:

"A few days ago, after the registration of the Science and Technology Biotechnology patent was completed, I talked with the investment director of IG Capital, the IG Biopharmaceutical Industry, and he put forward a point of view."

Li Shuyao was very interested in chatting with such big shots. She didn't realize that Li Miaomiao was already a big shot: "What about?"

Li Miaomiao continued: "He roughly means from artificial synthesis of endorphins to brain-computer connections. Zheng Li has fully proved that his development of enkephalin was not a flash of inspiration from a genius, but could continue to output."

"The valuation of Science and Technology Biotech cannot be valuated according to the patent authorization of endorphins and brain-computer connection mobile phones."

"The greatest value of Science and Technology Biotechnology lies in Zheng Li. He has completed two monopoly patent research and developments in biomedical fields at the age of 20. His future is limitless."

"Science and Technology Biotech should be valued from its source, and we should be valued based on Zheng Li's R&D capabilities."

Li Shuyao couldn't help it: "The problem is that this kind of thing cannot be valued. How many patents can Zheng Li guarantee that he can have in the future? How many of them are valuable like brain-computer connection and endorphins?"

“This is something completely unquantifiable.”

Li Miaomiao signaled her to calm down: "So young proposed not to give up this listing opportunity. IG Capital is willing to invest in the C round of Science and Technology Biotechnology without reason. As long as Zheng Li is still in the C round of Science and Technology Biotechnology for one day, even if he invests in the Z round, IG will participate in the Z round of investment."

Li Shuyao: "Don't you want to eat alone?"

Li Miaomiao: "Goldman Sachs and Temasek mean this. They both said that they are not urgent to go public. If the R&D of Sci-Tech Bio is short of funds, they are willing to participate in the next round of investment and are not willing to accept an unreasonable valuation."

"They are willing to wait ten or twenty years before going public after Zheng Li's scientific research capabilities are fully demonstrated."

"This is what Mr. Lei, who includes rice, means the same."

"As the underwriter, Kechuang Bio will compensate you with full compensation."

Li Shuyao: "It's not us, I'm just an intern. If you don't go public, the leaders of CICC will probably not be able to sleep during this period and will be depressed."

She couldn't help laughing when she thought of this.

Li Miaomiao continued: "Don't worry, I haven't finished it yet. After reporting the situation to Zheng Li, Zheng Li said that it would be this time to go public, but the valuation of the listing is indeed necessary to be re-discussed."

Li Shuyao asked in confusion: "Since IDG and Goldman Sachs are willing to follow up, then Science and Technology Biotech is not short of money, why are you in a hurry to go public?"

"Zheng Li wants to cash out the stocks himself and sell some of them to these investment banks."

Li Miaomiao shook her head and said, "I don't know what Zheng Li thinks. Although I think I am the person who knows him best in the company, I often don't know what he thinks."

Zheng Li’s idea is very simple. He does not need money or lacks money. He is soon to restore his spell casting ability. After he recovers his spell casting ability, the money is even more waste paper for him.

It doesn’t matter whether it will be launched early or later for Science and Technology Biotechnology. Since he has signed a contract, Zheng Li thought that it would be possible to go public early, and it would be considered as a benefit for employees.

Senior executives and middle-level executives have never been listed and cannot get options. If they go public, they can all get a part of their shares.

Li Miaomiao sighed and said, "I thought I could watch the show."

"If you don't go public, I don't have to work overtime every day."

Li Miaomiao: "If you don't want to do it, just quit your job and don't do it. You don't even have to quit your job during the internship and just say it to the personnel."

Li Shuyao: "I want to work hard, but I can see if I can stay in CICC."

Li Miaomiao: "If you want to come to Suzhou Dongwu Securities, I can help you get into the headquarters, or if you want to go to IG Capital, Goldman Sachs, Temasek and other things, I can also help you get an interview opportunity."

"As long as you are not acting outrageously, you can get in."

Li Shuyao sighed a little that the social resources her sister had were unimaginable: "Thank you, I will tell you if I wanted it."

Li Miaomiao saw that the other party was indifferent: "So if you only calculate the value of endorphins and brain-computer connections, you can value Science and Technology Biotechnology."

"This kind of prospectus is likely to not pass the board of directors."
Chapter completed!